Genome-wide association studies of exacerbations in children using long-acting beta2-agonists.

ABSTRACT:

Background

Some children with asthma experience exacerbations despite long-acting beta2-agonist (LABA) treatment. While this variability is partly caused by genetic variation, no genome-wide study until now has investigated which genetic factors associated with risk of exacerbations despite LABA use in children with asthma. We aimed to assess whether genetic variation was associated with exacerbations in children treated with LABA from a global consortium.

Methods

A meta-analysis of genome-wide association studies (meta-GWAS) was performed in 1,425 children and young adults with asthma (age 6-21 years) with reported regular use of LABA from six studies within the PiCA consortium using a random effects model. The primary outcome of each study was defined as any exacerbation w

SUBMITTER: Slob EMA 

PROVIDER: S-EPMC8328929 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature